The global yersinia diagnostics market is anticipated to grow significantly over the forecast period. Yersinia is a gram-positive rod-shaped bacteria belonging to the Enterobacteriaceae family. Pathogenic species of Yersinia include Yersinia pestis, Yersinia enterocolitica and Yersinia pseudotuberculosis. The Yersinia pestis species of this bacterium causes Bubonic plague and is carried by rodents and infective fleas. Some of the modes of transmission of these bacteria include rodent to human (direct contact), infective flea to human (direct contact) and human to human transmission (via pneumonic droplets).
On the other hand, the Yersinia enterocolitica and Yersinia pseudotuberculosis cause gastroenteritis. These bacteria are foodborne and the disease (Yersiniosis) caused by them includes symptoms, such as gastroenteritis, diarrhea, and vomiting. On account of the nature of Yersiniosis, this disease is sometimes mistakenly diagnosed as Crohn’s disease and appendicitis.
The relatively higher occurrence rate of Bubonic plague in the U.S. (according to the U.S. CDC, approximately 80% of the plague cases in the U.S. were diagnosed to be Bubonic plague) and the relatively high prevalence of Yersiniosis in Northern Europe, Scandinavian countries and Japan are some of the significant growth drivers of this market. In addition, the emergence of improved diagnostic technologies such as molecular diagnostics and growing patient awareness levels across the globe will serve the global Yersinia diagnostics market as drivers.
The presence of sophisticated healthcare infrastructure in North America (U.S. and Canada) coupled with high prophylactic initiatives undertaken by their respective governments make it a relatively matured market, in terms of growth rate. The Asia Pacific Yersinia diagnostics market, on the other hand, holds high future growth potential. The presence of untapped opportunities in emerging Asian economies and the high prevalence of Yersiniosis in Japan are some of the factors accounting for the aforementioned inference.
This research study encompasses a competitive landscape of the Yersinia diagnostics market. Revenue analysis, product benchmarking and strategic developments of key market players such as Abbott Laboratories, Affymetrix Inc., Bio-Rad Laboratories, Hologic, Roche, Becton Dickinson, Danaher Corporation, Gen-Probe and others are also provided in this report.
This report, by Grand View Research, takes a closer look at the Yersinia diagnostics industry, providing a holistic perspective on market dynamics, trends, supply, and demand. The report deep-dives into the market and segments it on multiple levels and providing key insights on a macro as well as micro-level. The study aims at providing granular information, regarding estimates and forecasts for key product segments including molecular diagnostics, gel microdroplets, liposomes, monoclonal antibodies, healthcare information technology, flow cytometry, chromatography, artificial intelligence, immunoassays, differential light scattering, diagnostic imaging and others. This report also encompasses market estimates and forecasts for key end-user segments namely hospitals, public health laboratories, commercial laboratories and others. The report also provides the same level of information for key regional markets.
This research report analyzes various factors, which have been driving and inhibiting the global Yersinia diagnostics market in the past. In addition, the report analyzes the impact of each driver and restraint on the market growth, which forms the base for the market forecast. The report also showcases the opportunities available in the market which may act as future drivers for the market.
This report has a service guarantee. We stand by our report quality.
We are in compliance with GDPR & CCPR norms. All interactions are confidential.
Design an exclusive study to serve your research needs.
Get your queries resolved from an industry expert.
"The quality of research they have done for us has been excellent..."
The most common concern for the governments of all Covid-19 hit nations is the excruciating need to screen for and test large numbers of patients for possible Sars-Cov-2 infection. As a result, most of them are facing major shortages in the supply for diagnostic kits to test for the virus. Diagnostics virology entities are under immense pressure to provide reliable testing kits, and there is a surge in demand for in-vitro or point-of-care testing capacities by labs across a large number of countries. The report will account for Covid19 as a key market contributor.